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Background: Men who have sex with men (MSM) now account for nearly half of all new HIV 
cases in Malaysia. There has been little research, however, characterizing the HIV care 
continuum among MSM living with HIV in Malaysia. This study describes the HIV care 
continuum and examines factors associated with HIV viral non-suppression among newly 
diagnosed MSM living with HIV in Kuala Lumpur, Malaysia.  
Methods: We enrolled 163 MSM living with HIV who were in care at a major university hospital 
in Kuala Lumpur, Malaysia. Participants completed a self-administered questionnaire. Electronic 
medical chart review also provided data on engagement in the care continuum, including CD4 
counts and HIV viral loads. Bivariate and multivariable logistic regression was used to identify 
correlates of HIV viral non-suppression. 
Results: 94.4% of this sample is currently on ART while 79.7% self-reported 100% adherence to 
medication. Nearly 80% of this population were optimally virally suppressed at <20 copies/mL. 
In the multivariable model, not having a full-time job (aOR = 6.25; 95% CI = 1.53 – 25.49; p = 
0.011) and being single (aOR = 9.15; CI = 1.07 – 78.21; p = 0.043) were associated with viral 
non-suppression (viral load of 200 copies/mL or more). 9.8% of all participants reported active 
(last 30 days) chemsex participation while nearly 40% indicated severe depression symptoms. 
Conclusions: This is the first study to describe the HIV care continuum on MSM from Malaysia. 
Though many MSM in this sample were able to achieve viral suppression, others continue to 
face socioeconomic barriers to treatment and retention in care. Future studies should recruit from 
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HIV in men who have sex with men 
Globally, men who have sex with men (MSM) have been disproportionately affected by HIV.1  
Although AIDS-related mortality has gradually declined over the last decade,2 many countries 
are experiencing re-emergent epidemics driven by sexual transmission, particularly among 
MSM.3 In several high-income Western European countries, Australia and the United States, 
HIV infection rates in the general population decreased, but not in MSM.4 In some low- and 
middle-income settings like Ghana and Peru, MSM were the predominant contributor to HIV.5 In 
the Asia-Pacific region, over 75% of new HIV infections in 2018 were among key populations 
and their sexual partners, especially young gay men (age 15 to 24) and other young MSM.2  
HIV in Malaysia 
Malaysia still has one of the highest burdens of HIV in its region.2 Since the first case of HIV 
was detected in the country in 1986, the total number of HIV diagnoses in Malaysia is estimated 
to be 118,883 with a national adult prevalence of 0.4%.6 By the end of 2018, there were 87,041 
living with HIV in Malaysia.6 The Malaysian epidemic is characterized by significant regional 
variations in severity: three states – Selangor, Kuala Lumpur and Putra Jaya, and Johor –
accounted for approximately half of PWH in Malaysia.6  
Historically, Malaysia’s HIV epidemic was primarily driven by people who inject drugs (PWID), 
which accounted for 83% of reported cases in 1996.6 In stark contrast, new HIV infections by 
sexual transmission among MSM in 1996 was 2%.6 This trend has reversed in recent years, with 
sexual transmission among MSM leading 56% of new HIV infections in 2018, while new 
infections among PWID declined to 3%.6  
5 
 
MSM and HIV in Malaysia 
Malaysia has the second highest HIV prevalence among gay men and other MSM in the Asia-
Pacific region after Indonesia.2 As of 2017, 21.6% of MSM in Malaysia were estimated to be 
HIV-infected, more than doubling from 8.9% three years prior.7 This trend was also seen in 
Kuala Lumpur, Malaysia’s largest and most urbanized city, where prevalence increased twofold, 
from 22% in 2014 to 43.3% in 2017.7 By the end of 2017, more than half (56.7%) of MSM were 
unaware of their HIV status.8 
This growing epidemic among MSM has been associated with several high-risk behaviors. HIV-
positive MSM in Malaysia showed higher rates of unprotected anal intercourse,9,10 multiple sex 
partners, and group sex.10,11 Up to 13%12 of Malaysian MSM have engaged in ‘chemsex’ at least 
once in their lifetime,13 which is the use of psychoactive drugs, particularly stimulants, to 
enhance sexual pleasure,13 which are significantly associated with HIV infection.14 Additionally, 
those who engaged in chemsex were more likely to have multiple sex partners, engage in group 
sex, show inconsistent condom use, and to have previously acquired sexually transmitted 
infections (STIs).12,15 MSM have also reported high use of geosocial sexual networking phone 
applications to find sex partners, which has been associated with increased engagement in 
chemsex,15 reduced condom use16,17 and increased STIs.17 
These findings are of concern for HIV prevention as substance abuse is likely to be part of the 
overlapping health problems (‘syndemics’) that put Malaysian MSM at high risk for HIV/STI 
infection and transmission.14,18-21 There are also implications for HIV treatment as alcohol and 
drug use was independently associated with antiretroviral therapy (ART) treatment non-
adherence.22,23 Amphetamine-type stimulants (ATS) use, particularly methamphetamine, was 
more strongly linked to engagement in condomless sex than were other drugs.22 Previous 
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research has shown that alcohol and substance use by MSM as means to cope with HIV-related 
stress can lead to more depressive symptoms and even cognitive impairment.23  
In addition, Malaysian MSM face long-standing religious, cultural, and legal prohibitions of drug 
use and homosexuality, which exacerbate the dual burden of social stigma and discrimination 
and limit their access to successful and equitable delivery of existing HIV prevention efforts, 
further escalating the HIV epidemic.24,25 Same-sex sexual acts are punishable by imprisonment 
of 14 years to life2, institutionalizing and criminalizing homophobia at the national level. Muslim 
and all ethnic Malay MSM face further stigma26 internally and externally from their families and 
religious communities as homosexuality is a punishable sin under Sharia law,9 compounding 
their psychosocial struggles with conflicting identities.27  
HIV treatment in Malaysia 
In Malaysia, HIV care is primarily delivered through the public Ministry of Health system which 
provides no-cost care and no-cost first-line ART.28 First-line ART in Malaysia –primarily 
comprised of Efavirenz, Emtricitabine, Tenofovir disoproxil – is fully covered by the 
government while second-line therapy is partially subsidized.28  
The HIV care continuum framework is a widely utilized model to describe and evaluate the 
progress of PWH along the spectrum of engagement in HIV care.29 Steps in the care continuum 
include diagnosis, linkage and retention in HIV care, initiation of ART, adherence to ART, and 
viral suppression.30 Minimizing the gaps between these steps is essential for successful test-and-
treat29 and treatment as prevention (TasP) strategies,31 as well as for reducing HIV-related 
morality. Optimizing engagement and retention in the continuum is also necessary for patients to 
achieve and maintain viral suppression.32,33  
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This framework was also recognized and adopted in the Joint United Nations Programme on 
HIV/AIDS’ (UNAIDS) 90-90-90 target for the year 2020: 90% of all PWH know their HIV 
status, 90% of those who know their status receive sustained ART, and 90% of those receiving 
ART be virally suppressed.34  
While Malaysia has made progress in the scale-up of HIV testing and universal access to no-cost 
ART for all Malaysian PWH,6 several areas of the care continuum remain suboptimal. As of 
2019, the Ministry of Health estimated that 86% of PWH were aware of their status, while 48% 
of PWH were receiving ART.2 The latest survey on ART initiation among Malaysian MSM 
indicated that 13.5% were currently on treatment.7 Moreover, there is no data on the proportion 
of PWH achieving HIV viral suppression for 2019 (UNAIDS reported 42% in 2018).8 It is 
difficult to assess at which of these points MSM PWH are falling off because the Malaysian 
Ministry of Health does not aggregate HIV care continuum results by key populations.  
Linkage to HIV care, initiation and retention on ART and HIV viral suppression are key to 
reducing mortality among PWH and preventing onward transmission of HIV. Given the 
suboptimal outcomes for PWH in Malaysia, particularly among MSM, the present study will 
evaluate the barriers and facilitators of linkage to HIV care, initiation and retention on ART, and 
achievement of HIV viral suppression among a sample of newly diagnosed HIV+ MSM in 
Greater Kuala Lumpur. Specifically, the study will examine the proportion of participants who 








Participants (n = 163) were recruited using venue-based convenience sampling at the University 
Malaya Medical Centre’s (UMMC) HIV clinic in Kuala Lumpur. One of the largest HIV clinics 
in Malaysia, UMMC provides ongoing HIV care to approximately 1700 PWH, with an average 
of 100 to 120 PWH encounters each week. Inclusion criteria were: 1) cisgender male; 2) ≥ 18 
years of age; 3) screened positive for HIV in the last 6 to 60 months; 4) identify as man who has 
sex with other men; 5) able to speak Bahasa Malaysia, Mandarin, or English; 6) able to provide 
informed consent; and 7) willing to consent to provide a release of medical information 
authorization for health records associated with their HIV care and treatment at UMMC. 
Patients with appointments were pre-screened for eligibility based on their electronic medical 
records and recruited during their waiting time. Walk-in patients were also reviewed for 
eligibility during their visit. Study flyers were posted on the wall of exam rooms and physicians 
were given study leaflets share with potentially eligible patients. Inpatient wards were also 
regularly checked for study candidates.  
Procedures 
Following informed consent, participants were self-administered a questionnaire using a tablet or 
laptop in a designated private area of the clinic. The questionnaire was programmed and 
administered using Qualtrics (Qualtrics, Inc., Provo, Utah, USA) online survey software. All 
study materials were translated into in English, Mandarin, and Bahasa Malaysia. All participants 
were offered the opportunity to enter a drawing for a free tablet computer for their participation 





Questionnaire measures included sociodemographic factors, including age, ethnicity, primary 
language, religion, country of birth, highest level of education achieved, employment status, 
relationship status, monthly income, and housing status.  
Lifetime and recent (last 30 days) alcohol and drug use were also measured, including alcohol, 
amphetamine-type stimulants (ATS), primarily methamphetamine; ecstasy / MDMA (3,4-
Methylenedioxymethamphetamine); heroin or other opioids, including prescription narcotics; 
cocaine; foxy,35 a synthetic tryptamine (5-methoxy-N, N-diisopropyltryptamine;35 GHB/GBL 
(Gamma‐Hydroxybutyrate); marijuana; ketamine; benzodiazepines; and LSD (lysergic acid 
diethylamide). Lifetime and recent (last 30 days) engagement in chemsex, defined as any use of 
ATS, ecstasy / MDMA, or GHB / GBL, prior to or during sexual activity.  
Participants were also asked to answer questions on their sexually transmitted infection (STI) 
and HIV history, such as self-reported date of diagnosis, visit history, CD4 and HIV viral load 
test information, as well as their antiretroviral therapy (ART) regimen and adherence. Other 
questions were on barriers to getting HIV care such as financial cost, lack of transportation, wait 
time, and employer leave policy.  
Depression was assessed using the Center for Epidemiologic Studies Short Depression Scale 
(CESD-10)36. The scale had a possible range of 0 to 30, and a previously validated37 cutoff score 
of 10 or higher was used to classify those with severe depressive symptoms. On average, it took 




Electronic Medical Chart Review 
Data collected during the chart review include: all UMMC HIV care visit encounter dates, all 
CD4 count and HIV Viral Load (VL) test dates and laboratory results, date of HIV diagnosis, 
date of antiretroviral treatment (ART) initiation, interruptions or changes in ART regimen, 
current diagnoses, current non-ART medications, and any notable background information of the 
participant recorded by the doctor.  
HIV-related Measures 
Several important HIV-related measures collected from the questionnaire and/or medical chart 
review will be used to describe the HIV care continuum of participants. Questionnaire measures 
include self-reported STI and HIV testing and diagnosis history, HIV-care visit history, CD4 and 
HIV viral load laboratory test results as, and ART adherence as best as they can recall. 
Participants were also asked to report social barriers to HIV care such as financial costs, wait 
time, ability to leave school or work, and access to transportation.  
Table 1 describes measures of the HIV care continuum extracted using responses to the 
questionnaire and data from medical chart review.  
Ethics and Human Subjects Protection 
All participants were asked to provide consent for Release of Information (ROI) of their health 
records and medical information related to their care at UMMC. This authorization was required 
for participation in the study. 
This study was approved by the Institutional Review Boards for Yale University and the 





Frequencies and descriptive statistics were used to characterize the participants. We used 
bivariate logistic regression to examine possible sociodemographic and HIV care-related 
predictors of viral non-suppression (defined as detectable load > 200 copies/mL). We ran a 
multivariable logistic regression analysis using independent variables with statistical significance 
at the p ≤ 0.10 level. Odds ratios with 95% confidence intervals were reported. All analyses were 
conducted in IBM SPSS Statistics 26 (Chicago, IL). 
Results 
Description of sample 
The mean age was 35.4 years (SD = 8.4). (Table 2). Over half (54.6%) were Chinese, followed 
by Malay (35.0%). Buddhism (35.6%) and Islam (35.6%) were the two most popular religions. 
Majority were highly educated (66.3%), with a bachelor’s degree or beyond. 80.4% had a full-
time job and the mean monthly income of the whole sample was USD 1,466.32 (SD = 1,418.93). 
A little over half (54.6%) were single, divorced, or separated from their spouse. The majority 
(92.7%) of this population had stable housing.  
Lifetime and active substance use history are illustrated in Figure 1. Alcohol (66.3%), ATS 
(33.1%), ecstasy (27.0%), and GHB (20.9%) were the most used drugs across the lifetime. 
Similarly, alcohol (39.3%), ATS (11.7%), GHB (6.1%), and ecstasy (3.7%) were the most used 
drugs during the previous 30 days. Opioids were among the least used drugs across the lifetime 
(1.2%) and last 30 days (0.6%).  Chemsex across the lifetime was reported by 39.9% of 
participants, with 9.8% having engaged in chemsex in the last 30 days. Lifetime drug injection 
behavior was reported by 9.2% of participants and 1.8% had injected drugs in the last 30 days.    
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Lifetime STI testing and diagnosis history is depicted in Figure 2. Over half of participants 
(50.9%) reported being previously diagnosed with Syphilis, with lower proportions having been 
ever diagnosed with gonorrhea (13.5%), hepatitis B (11.0%), chlamydia (7.4%), and hepatitis c 
(4.9%).  
Of all the participants, 39.9% reported a CESD score above 10, which indicates higher levels of 
depression symptoms in this group.  
HIV Care Continuum 
Figure 3 illustrates the proportion of study participants’ successes along the cascade of HIV care. 
The majority (54.6%, Figure 4) were diagnosed in a private hospital or clinic and on average, 
lived with HIV for 2.36 years (SD = 1.34). Mean time from HIV diagnosis to linkage to HIV 
care among this sample was 4.14 months (SD = 8.42). In correspondence with the eligibility 
criteria, 100% of this study sample has been positively diagnosed for HIV and have made at least 
one HIV care visit in the last 12 months. At baseline, 11% had a viral load higher than one 
million copies/mL and 30.1% had a CD4 count of less than 100. Nearly all (99.4%) self-reported 
that they are on ART. On average, time from HIV diagnosis to ART initiation was 2.20 months 
(SD = 3.39). Self-reports of adherence during the past 30 days were high, with levels of 94.4%, 
93.8%, and 75.3% for adherence levels of 80% or more, 90% or more, and 100%, respectively. 
At the <200 copies/mL cut-off level, 151 (92.6%) achieved viral suppression, while 130 (79.7%) 
achieved optimal suppression at a more conservative cut-off of <20 copies/mL. A majority 





Correlates of HIV viral non-suppression 
Of all the participants, only those who had at least one viral load test in the last 18 months (N = 
160) were included in the final bivariate and multivariate logistic regression models. At the 
bivariate level, participants who were ethnic Malay (OR = 2.83; 95% CI = 0.85 – 9.37; p = 
0.089), employed less than full-time (OR = 6.89; 95% CI = 2.02 – 23.46; p = 0.002), single (OR 
= 10.14; 95% CI = 1.28 – 80.6; p = 0.028), had a baseline CD4 count ≤ 100 cells/mm3 (OR = 
3.65; 95% CI = 1.10 – 12.15; p = 0.035), or were initially diagnosed in a government clinic or 
hospital (OR = 5.59; 95% CI = 1.59 – 19.60; p = 0.007) were significantly more likely to have a 
detectable HIV viral load in the previous 18 months. Participants who were initially diagnosed in 
a private clinic, however, were significant less likely to have a detectable HIV viral load in the 
last 18 months (OR = 0.25; 95% CI = 0.06 – 0.95; p = 0.042). In the multivariable model, not 
having a full-time job and being single were associated with viral non-suppression (viral load of 
200 copies/mL or more). Those who did not have a full-time job had 6-fold higher odds of 
having a detectable viral load (aOR = 6.25; 95% CI = 1.53 – 25.49; p = 0.011) compared to those 
who did. Participants who reported that they were single were 9 (aOR = 9.15; CI = 1.07 – 78.21; 
p = 0.043) times more likely to have a detectable viral load compared to non-single participants.  
Discussion 
To our knowledge, this is the first study to describe the HIV care continuum among MSM living 
with HIV in Malaysia. Results showed nearly all participants were on ART (99.4%) and the 
majority had achieved viral suppression (79.7% virally suppressed at <20 copies/mL) and 
adherence (75.3% adherent to ART = 100%). In this sample, opportunities remain for 
minimizing time between steps in the cascade. On average, there was a 4-month delay in linkage 
to care and 2-month period before ART initiation. The overall level of success was likely 
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possible due to UMMC’s unique position as a quasi-public institution with more independence. 
These findings may not be generalizable to all HIV-positive MSM in Malaysia, as this sample 
was recruited from a clinic and already engaged in care. Future studies should sample from a 
wider range of venues and include those disengaged from care. 
In this study, HIV viral non-suppression was associated with unstable employment. Individuals 
with employment less than full-time were more likely to have a detectable viral load than those 
with full-time employment. This finding can allude to financial limitations experienced by 
individuals with less than full-time employment. Previous studies have demonstrated 
associations between lower socioeconomic status (SES) and worse adherence and overall 
treatment outcomes38-40. Among this sample, 25.8%, 30.1%, and 14.1% said financial costs 
prevented them from receiving a CD4 test, HIV viral load test, and ART, respectively. Financial 
constraints could also explain why three participants did not have a viral load test within the last 
18 months. For some patients at UMMC, even subsidized viral load test costs can be 
burdensome. 
Being single (including divorced and separated) was also independently associated with viral 
non-suppression. Compared to those in relationship, single people had ten times the odds of viral 
non-suppression. This aligns with other findings that social support in the form relationships has 
been associated with better ART adherence41,42 and lower viral loads among MSM.43,44 These 
results suggest that interventions promoting relationship and social support can benefit treatment 
outcomes in HIV-positive MSM.  
Additional factors associated with viral non-suppression were the location of HIV diagnosis, 
CD4 count at baseline, and Malay ethnicity. These results follow that of prior studies which 
found an association between lower baseline CD4 cell count and greater risk of viral 
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rebound.45,46 Baseline CD4 count has also been shown to be a better predictor of viral 
suppression that baseline viral load.47 Overall, 11% and 30.1% of this group had baseline viral 
loads higher than one million copies/mL and baseline CD4 counts less than 100, respectively, 
indicating that many patients do not find out they are HIV-positive for a long time. The 
significance of location of HIV diagnosis may be explained by participants’ financial abilities. 
Private health care recipients may not experience financial barriers to seeking care compared to 
their counterparts. Among our participants, 54.6% were diagnosed in a private hospital or clinic 
(Figure 4).  
Though not found to be statistically significant factors in viral suppression, lifetime alcohol and 
substance use among this sample were fairly high (Figure 1). In particular, lifetime alcohol use 
was highest at 66.3% followed by poppers (44.8%), ATS (33.1%) and ecstasy (27.0%). These 
percentages drastically reduced for active use. One explanation may be that recently diagnosed 
PWH engage in less transmission risk behaviors immediately after their diagnosis.48 Social 
desirability bias may also be at play, with participants choosing responses that are more socially 
acceptable in Malaysia.49 Future studies should test for longer windows of “active use,” from 90 
days up to a year.  
Despite our results, alcohol and drug use among PWH should continue to be studied for its 
impact on other aspects of HIV care. This study observed higher levels of lifetime (39.9%) and 
active (9.8%) chemsex participation than seen in unpublished data (lifetime = 21.8%, active = 
6.2%) from a study of HIV-Syphilis co-infection among MSM in Malaysia.50 PWH who use 
alcohol and drugs to cope with HIV-related stress are less likely to be adherent to ART.41,51,52 
Furthermore, nearly half (39.9%) of this sample reported high levels of depression symptoms, 
which has also been associated with nonadherence to ART.52,53  
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In the multivariable analysis, two covariates remained significant. Not having full-time 
employment was associated with 6.25 times the odds of non-viral suppression compared with 
those who did. Individuals who were single were 9.15 times more likely to be virally non-
suppressed than those in a relationship. All significant covariates in this multivariate model were 
social measures, suggesting that socioeconomic statuses of HIV-positive MSM are important 
parts of successful care and treatment. Clinicians should ask more non-clinical questions and 
document these aspects of their patients. Future studies should incorporate social measures 
beyond those included here.  
There were several limitations in this study. First, these results may not be generalizable to those 
who are not engaged in care or those who progressed to death without being linked to care, as 
this population was recruited from a clinic. We also lacked medical chart data for participants 
who may have previously received HIV care outside of UMMC. In general, quality of the data 
captured through UMMC’s electronic medical records (EMR) was varied and dependent on the 
physician in charge. Aside from laboratory test results, all EMR were in text form and not 
standardized across patients. Critical information for some, such as HIV diagnoses and ART 
initiation dates, did not match self-reported dates. Access to EMR in general was restrictive with 
clinicians themselves only being able to view patient data up to 24 hours within a care visit. 
Clinicians also had no access to important patient information outside of their department, such 
as psychiatric comorbidities or prescriptions for other illnesses.  
Conclusions 
Despite these limitations, this study is the first to evaluate the HIV care continuum in MSM from 
Kuala Lumpur. While these results indicate that many Malaysian HIV-positive MSM linked to 
care are able to achieve viral suppression, it also highlights potential socioeconomic barriers 
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faced by this population. Future efforts should focus on evaluating other social barriers faced by 





Table 1. Measurement of the HIV care continuum 
Variable Source Measurement Definition 
Linkage to HIV 
care 
Self-reported HIV diagnosis 
on questionnaire; HIV care 
visit dates from chart review 
Binary (0,1) Completion of at least 
one HIV care clinic 
visit within 12 months 
of diagnosis 
Time to linkage 
to HIV care 
Self-reported HIV diagnosis 
on questionnaire; HIV care 
visit dates from chart review 
Continuous 
(months) 
Time (months) between 
the date of self-reported 
HIV diagnosis and the 
completion of the first 
HIV care clinic visit 
Initiation of 
ART 
Self-reported date of 
initiation of ART and 
recorded initiation date on 
chart review 
Binary (0,1) Initiation of ART, 
defined as the patient 





Self-reported date of HIV 
diagnosis on questionnaire; 
self-reported date of 
initiation of ART and 




Time (months) between 
the date of first HIV 
care clinic visit and 




Self-reported percent of 
doses completed in last 30 
days on questionnaire 
Self-reported 
percent of doses 
completed in last 
30 days 
Self-reported adherence 
during the past 30 days 










Most recent HIV-RNA 














Table 2. Characteristics of study population (n = 163) 
Characteristic n (%)* 
Age (years), mean ± SD 
Ethnicity 
     Malay 
     Chinese 
     Indian 
     Other 
Religion 







     Buddhism 58 (35.6) 
     Christianity 
     Hinduism 
     Islam 
     None/Atheist/Agnostic 







     Less than high school 
     High school 





     Full Time 
     Part Time 
     Unemployed 







     Single 
     Boyfriend/Partner 
     Married 
     Divorced or separated 







     House/apartment alone 
     House/apartment with others 
     Hotel/motel/guesthouse 






Monthly Income (MYR), mean ± SD 6,389.63 ± 6183.11 
* Percentages may not sum to 100% due to rounding. 






Table 3. Unadjusted and adjusted associations between study variables and viral non-suppression (n = 160*) 
Characteristic n (%)† Unadjusted OR (95% CI) p 
Adjusted OR 
(95% CI) p 
Demographics 
Age (years): 18 – 24 10 (6.2) 1.38 (0.16, 11.94) 0.768   
Age (years): 25 – 34 77 (47.2) 0.76 (0.23, 2.49) 0.643   
Age (years): 35+ 74 (45.4) 1.21 (0.37, 3.94) 0.749   
Ethnicity: Malay 57 (35.0) 2.83 (0.85, 9.37) 0.089 2.94 (0.73, 11.84) 0.130 
Ethnicity: Chinese 89 (54.6) 0.58 (0.17, 1.90) 0.363   
Education: Less than college 55 (33.7) 2.08 (0.64, 6.80) 0.224   
Employment: Not full time 32 (19.6) 6.89 (2.02, 23.46) 0.002 6.25 (1.53, 25.49) 0.011 
Income (MYR): Low income, <100 15 (9.2) 2.08 (0.41, 10.51) 0.377   
Relationship Status: Single 89 (54.6) 10.14 (1.28, 80.6) 0.028 9.15 (1.07, 78.21) 0.043 
Housing: Unstable 7 (4.3) 2.08 (0.23, 18.82) 0.516   
HIV Care-related 
CD4 count at baseline: 100 cells/mm3 or less 50 (30.7) 3.65 (1.10, 12.16) 0.035 1.82 (0.45, 7.29) 0.400 
VL at baseline: 1 million copies/mL or more 18 (11.0) 2.93 (0.72, 12.03) 0.135   
VL at baseline: 2 million copies/mL or more 8 (4.9) 0.0 (0.0, 0.0) 0.999   
Switch in ART regimen: At least once 40 (24.5) 0.67 (0.14, 3.23) 0.614   
HIV-related hospitalization: At least once 4 (2.5) 0.0 (0.0, 0.0) 0.999   
Location of HIV diagnosis: gov’t 49 (30.1) 5.59 (1.59, 19.60) 0.007   
Location of HIV diagnosis: private 89 (54.6) 0.25 (0.06, 0.95) 0.042 0.40 (0.09, 1.76) 0.226 
Location of first care since diagnosis: gov’t 48 (29.4) 1.05 (0.25, 4.38) 0.951   
Location of first care since diagnosis: private 31 (19.0) 2.02 (0.47, 8.59) 0.342   
Vitamin training: never received 10 (6.1) 3.50 (0.65, 18.72) 0.143   
Substance Use 
Lifetime: Chemsex 65 (39.9) 0.71 (0.21, 2.47) 0.594   
Lifetime: Alcohol 108 (66.3) 1.02 (0.29, 3.55) 0.975   
Lifetime: Marijuana 33 (20.2) 0.33 (0.04, 2.65) 0.297   
Lifetime: ATS 54 (33.1) 0.98 (0.28, 3.41) 0.975   
Lifetime: Ecstasy (E, MDMA) 44 (27.0) 0.52 (0.11, 2.49) 0.414   
Lifetime: “Club” drugs ‡ 68 (41.7) 0.68 (0.20, 2.34) 0.535   
21 
 
Active: Chemsex 16 (9.8) 0.81 (0.10, 6.69) 0.842   
Active (last 30 days): Alcohol 64 (39.3) 0.50 (0.13, 1.94) 0.317   
Active (last 30 days): Marijuana 5 (3.1) 0.0 (0.0, 0.0) 0.999   
Active (last 30 days): ATS 19 (11.7) 0.66 (0.08, 5.39) 0.695   
Active (last 30 days): Ecstasy (E, MDMA) 6 (3.7) 0.0 (0.0, 0.0) 0.999   
Active (last 30 days): “Club” drugs 20 (12.3) 0.66 (0.08, 5.39) 0.695   
Depression (CES-D score above 10) 65 (39.9) 1.11 (0.34, 3.66) 0.866   
*Key: OR = odds ratio; aOR = adjusted odds ratio; ATS = Amphetamine-type stimulants; E = Ecstasy; MDMA = 3,4-Methylenedioxy
methamphetamine; CES-D = Center for Epidemiological Studies Depression Scale. 
†Three cases whose most recent viral load test was > 18 months were removed.  
‡ Number of cases for each variable may not sum to total number of participants due to missing values.  
















Figure 1.  Lifetime and active substance abuse history (n = 163) 
 













Figure 3. The HIV care continuum among recently diagnosed HIV-positive men who have sex with men in Kuala Lumpur, 
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